Comparing Avadel Pharmaceuticals PLC. (AVDL) and Acura Pharmaceuticals (ACUR)
Avadel Pharmaceuticals PLC. (NASDAQ: AVDL) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
This table compares Avadel Pharmaceuticals PLC. and Acura Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Avadel Pharmaceuticals PLC.||44.47%||33.92%||8.94%|
This is a breakdown of current ratings and price targets for Avadel Pharmaceuticals PLC. and Acura Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Avadel Pharmaceuticals PLC.||0||0||2||0||3.00|
Avadel Pharmaceuticals PLC. currently has a consensus target price of $25.00, indicating a potential upside of 170.86%. Given Avadel Pharmaceuticals PLC.’s higher possible upside, research analysts plainly believe Avadel Pharmaceuticals PLC. is more favorable than Acura Pharmaceuticals.
Insider & Institutional Ownership
69.8% of Avadel Pharmaceuticals PLC. shares are owned by institutional investors. Comparatively, 9.4% of Acura Pharmaceuticals shares are owned by institutional investors. 5.1% of Avadel Pharmaceuticals PLC. shares are owned by insiders. Comparatively, 5.6% of Acura Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Avadel Pharmaceuticals PLC. has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
Earnings and Valuation
This table compares Avadel Pharmaceuticals PLC. and Acura Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Avadel Pharmaceuticals PLC.||$150.25 million||2.46||-$41.27 million||$1.90||4.86|
|Acura Pharmaceuticals||$4.46 million||1.98||-$7.38 million||($0.14)||-3.04|
Acura Pharmaceuticals has higher revenue, but lower earnings than Avadel Pharmaceuticals PLC.. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Avadel Pharmaceuticals PLC., indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals PLC. beats Acura Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
About Avadel Pharmaceuticals PLC.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
About Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.
Receive News & Stock Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related stocks with our FREE daily email newsletter.